You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTranilast
Accession NumberDB07615
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
Structure
Thumb
Synonyms
2-{[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino}benzoic acid
External Identifiers
  • MK 341
  • MK-341
  • MK341
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RizabenNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIHVF50SMY6E
CAS number53902-12-8
WeightAverage: 327.3313
Monoisotopic: 327.110672659
Chemical FormulaC18H17NO5
InChI KeyNZHGWWWHIYHZNX-CSKARUKUSA-N
InChI
InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
IUPAC Name
2-[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enamido]benzoic acid
SMILES
COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC
Pharmacology
IndicationFor the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Hematopoietic prostaglandin D synthaseProteinunknownNot AvailableHumanO60760 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tranilast is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tranilast is combined with 19-norandrostenedione.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Tranilast.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Tranilast.Vet Approved
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Tranilast.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Tranilast.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Tranilast.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Tranilast is combined with 4-Androstenedione.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Tranilast.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Tranilast is combined with 5-androstenedione.Experimental, Illicit
AbciximabTranilast may increase the anticoagulant activities of Abciximab.Approved
AcebutololTranilast may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tranilast.Approved
AcenocoumarolTranilast may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinTranilast may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tranilast.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tranilast is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Alendronic acid.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Tranilast.Approved, Investigational
AliskirenTranilast may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololTranilast may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tranilast.Approved, Investigational
AlteplaseTranilast may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Tranilast may increase the anticoagulant activities of ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Amcinonide.Approved
AmikacinTranilast may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideTranilast may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Aminosalicylic Acid.Approved
AmobarbitalThe metabolism of Tranilast can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Tranilast.Approved
AmphetamineAmphetamine may decrease the sedative activities of Tranilast.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranilast.Approved, Investigational
AmrubicinTranilast may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Tranilast.Investigational
AnagrelideTranilast may increase the anticoagulant activities of Anagrelide.Approved
AncrodTranilast may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Tranilast is combined with Anecortave.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Tranilast.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Tranilast is combined with Anisodamine.Investigational
AnistreplaseTranilast may increase the anticoagulant activities of Anistreplase.Approved
annamycinTranilast may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tranilast.Approved
Antithrombin III humanTranilast may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Tranilast may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanThe risk or severity of adverse effects can be increased when Tranilast is combined with Apixaban.Approved
ApramycinTranilast may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Tranilast.Approved, Investigational
ArbekacinTranilast may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinTranilast may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanTranilast may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTranilast may decrease the antihypertensive activities of Arotinolol.Approved
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Tranilast.Approved
AstaxanthinTranilast may increase the anticoagulant activities of Astaxanthin.Investigational
AtenololTranilast may decrease the antihypertensive activities of Atenolol.Approved
AtosibanThe risk or severity of adverse effects can be increased when Tranilast is combined with Atosiban.Approved
Atracurium besylateTranilast may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tranilast.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tranilast.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tranilast.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Tranilast.Experimental
BalsalazideTranilast may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarbexacloneThe metabolism of Tranilast can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Tranilast can be increased when combined with Barbital.Illicit
BatroxobinTranilast may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminTranilast may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Tranilast is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTranilast may decrease the antihypertensive activities of Befunolol.Experimental
BemiparinTranilast may increase the anticoagulant activities of Bemiparin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tranilast.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tranilast.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tranilast.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Tranilast.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Tranilast.Approved, Illicit
Benzylpenicilloyl PolylysineTranilast may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tranilast.Investigational
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Tranilast.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Betamethasone.Approved, Vet Approved
BetaxololTranilast may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Betulinic Acid.Investigational
BevantololTranilast may decrease the antihypertensive activities of Bevantolol.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Tranilast.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tranilast.Approved, Investigational
BisoprololTranilast may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTranilast may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTranilast may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tranilast.Approved
BucillamineThe risk or severity of adverse effects can be increased when Tranilast is combined with Bucillamine.Investigational
BucindololBucindolol may increase the hypotensive activities of Tranilast.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Budesonide.Approved
BufuralolTranilast may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideTranilast may decrease the diuretic activities of Bumetanide.Approved
BupranololTranilast may decrease the antihypertensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Tranilast.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Tranilast.Approved
ButylphthalideTranilast may increase the antiplatelet activities of Butylphthalide.Investigational
CalciumThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tranilast.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Tranilast.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tranilast.Experimental
CangrelorTranilast may increase the anticoagulant activities of Cangrelor.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tranilast.Approved
CarbomycinThe metabolism of Tranilast can be decreased when combined with Carbomycin.Vet Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tranilast.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tranilast.Approved, Vet Approved, Withdrawn
CarteololTranilast may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Tranilast.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Tranilast.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tranilast.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Tranilast is combined with Celecoxib.Approved, Investigational
CeliprololTranilast may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTranilast may increase the anticoagulant activities of Certoparin.Approved
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Tranilast.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tranilast.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tranilast.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Tranilast.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Tranilast.Illicit, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tranilast.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Ciclesonide.Approved, Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Tranilast.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tranilast.Approved
CilostazolTranilast may increase the anticoagulant activities of Cilostazol.Approved
CimetidineThe serum concentration of Tranilast can be increased when it is combined with Cimetidine.Approved
CinoxacinTranilast may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinTranilast may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidTranilast may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Tranilast can be decreased when combined with Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tranilast is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tranilast is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Tranilast is combined with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tranilast.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tranilast.Vet Approved
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Tranilast.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CollagenaseThe risk or severity of adverse effects can be increased when Tranilast is combined with Collagenase.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Tranilast.Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Tranilast is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Tranilast is combined with Curcumin.Investigational
CyclosporineTranilast may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tranilast.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Tranilast is combined with D-Limonene.Investigational
Dabigatran etexilateTranilast may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTranilast may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTranilast may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Tranilast.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Tranilast.Approved, Investigational
DaunorubicinTranilast may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Tranilast.Experimental
DeferasiroxThe risk or severity of adverse effects can be increased when Tranilast is combined with Deferasirox.Approved, Investigational
DefibrotideTranilast may increase the anticoagulant activities of Defibrotide.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Tranilast is combined with dehydroepiandrosterone sulfate.Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Tranilast is combined with dersalazine.Investigational
DesirudinTranilast may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin.Approved
DesmoteplaseTranilast may increase the anticoagulant activities of Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tranilast is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tranilast is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tranilast is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tranilast.Approved
DextranTranilast may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Tranilast may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Tranilast may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Tranilast may increase the anticoagulant activities of Dextran 75.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Tranilast.Approved, Illicit
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tranilast.Approved, Vet Approved
DicoumarolTranilast may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Tranilast.Approved, Illicit
DiflorasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Tranilast is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Tranilast is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tranilast.Approved
DihydrostreptomycinTranilast may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tranilast.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tranilast.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tranilast.Approved
DipyridamoleTranilast may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleTranilast may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DoxazosinDoxazosin may increase the hypotensive activities of Tranilast.Approved
DoxorubicinTranilast may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTranilast may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaTranilast may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Tranilast is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Tranilast is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Tranilast is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Tranilast is combined with Ebselen.Investigational
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Tranilast.Approved
Edetic AcidTranilast may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTranilast may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Tranilast can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Tranilast.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tranilast.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tranilast.Approved
EnoxacinTranilast may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinTranilast may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the antiplatelet activities of Tranilast.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Tranilast is combined with Epirizole.Approved
EpirubicinTranilast may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneTranilast may decrease the antihypertensive activities of Eplerenone.Approved
eplivanserineTranilast may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Tranilast.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tranilast.Approved
EptifibatideTranilast may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Tranilast is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tranilast is combined with Equilin.Approved
ErythromycinThe metabolism of Tranilast can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololTranilast may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tranilast is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tranilast is combined with Estrone sulfate.Approved
Etacrynic acidTranilast may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tranilast.Approved, Investigational
Ethyl biscoumacetateTranilast may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Tranilast is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Tranilast is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Tranilast is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Tranilast is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Tranilast.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Tranilast is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tranilast.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tranilast.Vet Approved
FibrinolysinTranilast may increase the anticoagulant activities of Fibrinolysin.Approved
FleroxacinTranilast may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tranilast.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Tranilast is combined with fluasterone.Investigational
FluconazoleThe serum concentration of Tranilast can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Tranilast.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fludrocortisone.Approved
FluindioneTranilast may increase the anticoagulant activities of Fluindione.Investigational
FlumequineTranilast may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tranilast is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Tranilast is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tranilast.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tranilast is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tranilast.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tranilast.Approved, Nutraceutical, Vet Approved
FondaparinuxTranilast may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTranilast may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tranilast.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tranilast is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tranilast.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Tranilast.Approved
FramycetinTranilast may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideTranilast may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateTranilast may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTranilast may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTranilast may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tranilast.Approved, Withdrawn
GemifloxacinTranilast may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTranilast may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTranilast may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATranilast may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GlucosamineGlucosamine may increase the antiplatelet activities of Tranilast.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Tranilast.Experimental
GrepafloxacinTranilast may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Tranilast.Approved, Vet Approved
HaloperidolThe risk or severity of adverse effects can be increased when Tranilast is combined with Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Tranilast.Approved, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Tranilast is combined with HE3286.Investigational
HeparinTranilast may increase the anticoagulant activities of Heparin.Approved, Investigational
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Tranilast.Approved
HexobarbitalThe metabolism of Tranilast can be increased when combined with Hexobarbital.Approved
HigenamineTranilast may increase the anticoagulant activities of Higenamine.Investigational
HirulogTranilast may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Tranilast.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tranilast.Approved, Investigational
HydralazineTranilast may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tranilast.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tranilast.Approved
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Tranilast.Approved
Hygromycin BTranilast may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Tranilast.Approved
IbudilastIbudilast may increase the antiplatelet activities of Tranilast.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tranilast.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Tranilast.Approved
Icosapent ethylTranilast may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdarubicinTranilast may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxTranilast may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilTranilast may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
IloprostIloprost may increase the antiplatelet activities of Tranilast.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tranilast.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tranilast.Approved
IndenololTranilast may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenTranilast may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tranilast.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Tranilast is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Tranilast.Withdrawn
INNO-206Tranilast may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tranilast.Approved, Investigational
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Tranilast.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Tranilast is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tranilast is combined with Istaroxime.Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Tranilast.Approved, Investigational
JosamycinThe metabolism of Tranilast can be decreased when combined with Josamycin.Approved
KanamycinTranilast may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
Kct 0809Tranilast may increase the anticoagulant activities of Kct 0809.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Kebuzone.Experimental
KetanserinTranilast may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Tranilast.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tranilast.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tranilast.Approved
KitasamycinThe metabolism of Tranilast can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Tranilast.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tranilast.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tranilast.Approved, Investigational
LepirudinTranilast may increase the anticoagulant activities of Lepirudin.Approved
LevobunololTranilast may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTranilast may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostLimaprost may increase the antiplatelet activities of Tranilast.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Tranilast.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tranilast.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Tranilast is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Tranilast.Approved
LomefloxacinTranilast may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tranilast.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tranilast.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Tranilast is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tranilast.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Tranilast is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tranilast.Vet Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tranilast.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium Sulfate.Approved, Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tranilast.Approved
ME-609The risk or severity of adverse effects can be increased when Tranilast is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tranilast.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tranilast.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Tranilast is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tranilast.Approved, Vet Approved
MephedroneMephedrone may decrease the sedative activities of Tranilast.Investigational
MephentermineMephentermine may decrease the sedative activities of Tranilast.Approved
MesalazineThe risk or severity of adverse effects can be increased when Tranilast is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Tranilast.Withdrawn
MethamphetamineMethamphetamine may decrease the sedative activities of Tranilast.Approved, Illicit
MethohexitalThe metabolism of Tranilast can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tranilast.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tranilast.Approved
MethylphenobarbitalThe metabolism of Tranilast can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTranilast may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tranilast.Approved
MetoprololTranilast may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTranilast may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Tranilast.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Tranilast.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Tranilast.Approved, Investigational, Vet Approved
MilrinoneMilrinone may increase the antiplatelet activities of Tranilast.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Tranilast.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tranilast.Approved
MivacuriumTranilast may increase the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe risk or severity of adverse effects can be increased when Tranilast is combined with Mizoribine.Investigational
MMDAMMDA may decrease the sedative activities of Tranilast.Experimental, Illicit
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tranilast.Approved
MometasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Mometasone.Approved, Vet Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Tranilast.Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tranilast.Approved
MoxifloxacinTranilast may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tranilast.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tranilast.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Tranilast.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Nabumetone.Approved
NadololTranilast may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTranilast may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTranilast may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe metabolism of Tranilast can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tranilast.Approved
NaftopidilTranilast may increase the antiplatelet activities of Naftopidil.Investigational
Nalidixic AcidTranilast may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tranilast.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Tranilast.Approved
NCX 1022The risk or severity of adverse effects can be increased when Tranilast is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Tranilast is combined with NCX 4016.Investigational
NeamineTranilast may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinTranilast may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTranilast may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tranilast.Approved
NetilmicinTranilast may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tranilast.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tranilast.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Tranilast is combined with Nitroaspirin.Investigational
NitroprussideTranilast may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Tranilast.Approved
NorfloxacinTranilast may increase the neuroexcitatory activities of Norfloxacin.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Tranilast.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Tranilast is combined with Obinutuzumab.Approved
OfloxacinTranilast may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandomycinThe metabolism of Tranilast can be decreased when combined with Oleandomycin.Vet Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Tranilast is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tranilast.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tranilast.Approved
OlsalazineTranilast may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Tranilast is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Tranilast.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Tranilast.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Tranilast is combined with Orgotein.Vet Approved
OtamixabanTranilast may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tranilast.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Tranilast.Approved
OxprenololTranilast may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tranilast.Withdrawn
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Tranilast.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tranilast is combined with Parecoxib.Approved
ParnaparinTranilast may increase the anticoagulant activities of Parnaparin.Approved
ParomomycinTranilast may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinTranilast may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTranilast may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTranilast may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Tranilast.Approved
PentobarbitalThe metabolism of Tranilast can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tranilast.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Tranilast.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tranilast.Approved
PhenindioneTranilast may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Tranilast can be increased when combined with Phenobarbital.Approved
PhenprocoumonTranilast may increase the anticoagulant activities of Phenprocoumon.Approved
PhenterminePhentermine may decrease the sedative activities of Tranilast.Approved, Illicit
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tranilast.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Tranilast.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tranilast.Approved, Investigational
PindololTranilast may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinTranilast may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideTranilast may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tranilast.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tranilast.Approved, Investigational
PlasminTranilast may increase the anticoagulant activities of Plasmin.Investigational
PlicamycinTranilast may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tranilast.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Tranilast.Approved, Investigational, Vet Approved
PractololTranilast may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tranilast.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Tranilast is combined with Prasterone.Approved, Nutraceutical
PrasugrelTranilast may increase the anticoagulant activities of Prasugrel.Approved
PrazosinPrazosin may increase the hypotensive activities of Tranilast.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Tranilast is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Tranilast can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Tranilast can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Tranilast is combined with Propacetamol.Approved
PropranololTranilast may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tranilast.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Tranilast.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tranilast.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tranilast.Vet Approved
Protein CTranilast may increase the anticoagulant activities of Protein C.Approved
Protein S humanTranilast may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTranilast may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTranilast may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Tranilast.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Tranilast.Investigational
PuromycinTranilast may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tranilast.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tranilast.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Tranilast.Experimental
RamatrobanTranilast may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tranilast.Approved
RapacuroniumTranilast may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tranilast.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tranilast.Experimental, Investigational
ReteplaseTranilast may increase the anticoagulant activities of Reteplase.Approved
ReviparinTranilast may increase the anticoagulant activities of Reviparin.Approved
RibostamycinTranilast may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RidogrelRidogrel may increase the antiplatelet activities of Tranilast.Approved
RifabutinThe serum concentration of Tranilast can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Tranilast can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Tranilast can be decreased when it is combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Risedronate.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Tranilast.Investigational
RivaroxabanTranilast may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Tranilast is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneTranilast may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RosoxacinTranilast may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tranilast.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Tranilast is combined with Salicylamide.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Tranilast.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tranilast.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tranilast.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tranilast.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tranilast.Investigational
SCH-530348SCH-530348 may increase the antiplatelet activities of Tranilast.Investigational
SecobarbitalThe metabolism of Tranilast can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagTranilast may increase the anticoagulant activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tranilast.Approved, Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Tranilast.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Tranilast.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Tranilast.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Tranilast.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Tranilast.Approved, Investigational
SisomicinTranilast may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SolithromycinThe metabolism of Tranilast can be decreased when combined with Solithromycin.Investigational
SotalolTranilast may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTranilast may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTranilast may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinTranilast may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tranilast.Approved
SpironolactoneTranilast may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Tranilast.Investigational
StreptokinaseTranilast may increase the anticoagulant activities of Streptokinase.Approved
StreptomycinTranilast may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTranilast may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Tranilast.Approved
SulfasalazineTranilast may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tranilast.Approved
SulodexideTranilast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tranilast.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tranilast.Approved, Withdrawn
TacrolimusTranilast may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tranilast.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tranilast.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Tranilast.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tranilast.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Tranilast.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Technetium Tc-99m Medronate.Approved
TelithromycinThe metabolism of Tranilast can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tranilast.Approved, Investigational
TemafloxacinTranilast may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Tranilast.Experimental, Investigational
TenecteplaseTranilast may increase the anticoagulant activities of Tenecteplase.Approved
TenofovirThe risk or severity of adverse effects can be increased when Tranilast is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tranilast.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tranilast is combined with Tepoxalin.Vet Approved
TerazosinTerazosin may increase the hypotensive activities of Tranilast.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Tranilast.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Tranilast.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Tranilast is combined with Teriflunomide.Approved
TesmilifeneTesmilifene may increase the antiplatelet activities of Tranilast.Investigational
ThiamylalThe metabolism of Tranilast can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Tranilast can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Tranilast.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tranilast.Approved
TicagrelorTranilast may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTranilast may increase the anticoagulant activities of Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Tiludronate.Approved, Vet Approved
TimololTranilast may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tranilast is combined with Tinoridine.Investigational
TinzaparinTranilast may increase the anticoagulant activities of Tinzaparin.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Tranilast.Approved
TipranavirTipranavir may increase the antiplatelet activities of Tranilast.Approved, Investigational
TirofibanTranilast may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tranilast is combined with Tixocortol.Approved
TobramycinTranilast may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tranilast.Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Tranilast.Approved, Vet Approved
TorasemideTranilast may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Tranilast is combined with Tositumomab.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tranilast.Approved
TrapidilTranilast may increase the antiplatelet activities of Trapidil.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tranilast.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tranilast.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTranilast may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tranilast.Approved, Vet Approved
TriflusalTranilast may increase the anticoagulant activities of Triflusal.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Tranilast.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Tranilast.Approved, Investigational
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tranilast.Approved
TroleandomycinThe metabolism of Tranilast can be decreased when combined with Troleandomycin.Approved
TrovafloxacinTranilast may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TylosinThe metabolism of Tranilast can be decreased when combined with Tylosin.Vet Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tranilast.Approved
UrokinaseTranilast may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Tranilast is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinTranilast may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tranilast.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tranilast.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Tranilast.Approved, Nutraceutical, Vet Approved
VorapaxarTranilast may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Tranilast.Approved, Investigational
WarfarinTranilast may increase the anticoagulant activities of Warfarin.Approved
WarfarinThe risk or severity of adverse effects can be increased when Tranilast is combined with Warfarin.Approved
XimelagatranTranilast may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Tranilast may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tranilast.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tranilast.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tranilast.Withdrawn
ZorubicinTranilast may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5905
Blood Brain Barrier-0.58
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.6922
P-glycoprotein inhibitor INon-inhibitor0.7716
P-glycoprotein inhibitor IINon-inhibitor0.5842
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.8054
CYP450 3A4 substrateSubstrate0.5548
CYP450 1A2 substrateNon-inhibitor0.9137
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9451
CYP450 2C19 inhibitorNon-inhibitor0.9167
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7384
Ames testNon AMES toxic0.6665
CarcinogenicityNon-carcinogens0.871
BiodegradationNot ready biodegradable0.8218
Rat acute toxicity2.4428 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9921
hERG inhibition (predictor II)Non-inhibitor0.8008
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0084 mg/mLALOGPS
logP2.89ALOGPS
logP3.56ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.55ChemAxon
pKa (Strongest Basic)-2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area84.86 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity91.52 m3·mol-1ChemAxon
Polarizability34.2 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cinnamic acid amides. These are amides of cinnamic acids. Cinnamic acid is an aromatic compound containing a benzene and a carboxylic acid group forming 3-phenylprop-2-enoic acid.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassCinnamic acids and derivatives
Sub ClassCinnamic acid amides
Direct ParentCinnamic acid amides
Alternative Parents
Substituents
  • Cinnamic acid amide
  • O-dimethoxybenzene
  • Dimethoxybenzene
  • N-arylamide
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Phenylpropene
  • Benzoic acid
  • Benzoic acid or derivatives
  • Methoxybenzene
  • Styrene
  • Phenol ether
  • Benzoyl
  • Anisole
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the conjugation of glutathione with a wide range of aryl halides and organic isothiocyanates. Also exhibits low glutathione-peroxidase activity towards cumene hydroperoxide.
Gene Name:
HPGDS
Uniprot ID:
O60760
Molecular Weight:
23343.65 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on September 15, 2010 15:24 / Updated on August 17, 2016 12:24